News & events

What's new

RSS
Feb 2023 (66) Jan 2023 (519) Dec 2022 (391) Nov 2022 (404) Oct 2022 (282) Sep 2022 (309) Aug 2022 (200) Jul 2022 (294) Jun 2022 (375) May 2022 (233) Apr 2022 (262) Mar 2022 (292) Feb 2022 (237)
Date Content
22/12/2022 Quarterly system demo - Q4 2022 , Online, 09:00 - 12:00 Amsterdam time (CET), from 21/12/2022 to 21/12/2022
22/12/2022 Human medicines European public assessment report (EPAR): Rizmoic, Naldemedine tosilate, Constipation, 18/02/2019, Additional monitoring, 7, Authorised
22/12/2022 Other: Clinical Trial Information System (CTIS) - Sponsor handbook
22/12/2022 Other: Questions and answers - Quarterly system demo - Q4 2022
22/12/2022 Human medicines European public assessment report (EPAR): Imvanex, modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus, Smallpox Vaccine; Monkeypox virus, 31/07/2013, Additional monitoring, Exceptional circumstances, 23, Authorised
22/12/2022 Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Osteoporosis, Postmenopausal; Osteoporosis, Additional monitoring, Authorised
22/12/2022 Human medicines European public assessment report (EPAR): Bridion, sugammadex, Neuromuscular Blockade, 25/07/2008, 21, Authorised
22/12/2022 Newsletter: CTIS newsflash - 12 December 2022
22/12/2022 Newsletter: CTIS newsflash - 5 December 2022
22/12/2022 Human medicines European public assessment report (EPAR): Posaconazole AHCL, posaconazole, Mycoses, 25/07/2019, Generic, 5, Authorised
22/12/2022 Other: European Medicines Agency's Data Protection notice concerning the Veterinary Info Day meeting on 16-17 February 2023
22/12/2022 Orphan designation: Pegylated adrenomedullin for the: Treatment of acute respiratory distress syndrome (ARDS), 27/07/2020, Positive
22/12/2022 Orphan designation: Human allogeneic bone-marrow-derived osteoblastic-like cells for the: Treatment of non-traumatic osteonecrosis, 05/08/2013, Positive
22/12/2022 Orphan designation: Human allogeneic bone-marrow-derived osteoblastic cells for the: Treatment of osteogenesis imperfecta, 10/08/2015, Positive
22/12/2022 Human medicines European public assessment report (EPAR): Quinsair, levofloxacin, Cystic Fibrosis; Respiratory Tract Infections, 25/03/2015, Additional monitoring, 15, Authorised
22/12/2022 Human medicines European public assessment report (EPAR): Mycapssa, Octreotide acetate, Acromegaly, 02/12/2022, Orphan, Authorised
22/12/2022 Human medicines European public assessment report (EPAR): Dificlir, fidaxomicin, Clostridium Infections, 05/12/2011, 17, Authorised
22/12/2022 Opinion on medicine for use outside EU: Fexinidazole Winthrop, fexinidazole, Trypanosomiasis, African, 15/11/2018, Positive opinion
22/12/2022 Human medicines European public assessment report (EPAR): Hepcludex, Bulevirtide acetate, Hepatitis D, Chronic, 31/07/2020, Orphan, Additional monitoring, Conditional approval, 8, Authorised
22/12/2022 Human medicines European public assessment report (EPAR): Exjade, deferasirox, beta-Thalassemia; Iron Overload, 28/08/2006, Additional monitoring, 51, Authorised
22/12/2022 Human medicines European public assessment report (EPAR): Esperoct, Turoctocog alfa pegol, Hemophilia A, 20/06/2019, Additional monitoring, 4, Authorised
22/12/2022 Human medicines European public assessment report (EPAR): Vipidia, alogliptin, Diabetes Mellitus, Type 2, 18/09/2013, 9, Authorised
22/12/2022 Opinion/decision on a Paediatric investigation plan (PIP): Rivogenlecleucel, PM: decision on the application for modification of an agreed PIP, P/0378/2019
22/12/2022 Human medicines European public assessment report (EPAR): Opsumit, Macitentan, Hypertension, Pulmonary, 20/12/2013, Orphan, 21, Authorised
22/12/2022 Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, benralizumab, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0388/2021
22/12/2022 Opinion/decision on a Paediatric investigation plan (PIP): Pradigastat, P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), P/0120/2014
22/12/2022 Human variations electronic application form (eAF) Q&A clinics – session 7 , Online, 11:30 - 12:00 Amsterdam time (CET), from 24/01/2023 to 24/01/2023
22/12/2022 Agenda: Agenda - Human variations electronic application form (eAF) Q&A clinics – session 6
22/12/2022 Human variations electronic application form (eAF) Q&A clinics – session 6 , Online, 15:30 - 16:00 Amsterdam time (CET), from 17/01/2023 to 17/01/2023
21/12/2022 Cancer Medicines Forum December 2022 , Online, from 20/12/2022 to 20/12/2022
21/12/2022 Union Product Database
21/12/2022 Human medicines European public assessment report (EPAR): Ronapreve, casirivimab, imdevimab, COVID-19 virus infection, 12/11/2021, Additional monitoring, 2, Authorised
21/12/2022 Referrals document: Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers for marketing authorisation holders / applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products
21/12/2022 Ninth Nitrosamine Implementation Oversight Group (NIOG) meeting , Online, from 21/11/2022 to 21/11/2022
21/12/2022 Human medicines European public assessment report (EPAR): Vizamyl, flutemetamol (18F), Radionuclide Imaging; Alzheimer Disease, 22/08/2014, 14, Authorised
21/12/2022 Human medicines European public assessment report (EPAR): Zaltrap, aflibercept, Colorectal Neoplasms, 01/02/2013, 13, Authorised
21/12/2022 Human medicines European public assessment report (EPAR): Eliquis, Apixaban, Arthroplasty; Venous Thromboembolism, 18/05/2011, 31, Authorised
21/12/2022 Human medicines European public assessment report (EPAR): Adcirca (previously Tadalafil Lilly), tadalafil, Hypertension, Pulmonary, 01/10/2008, 15, Authorised
21/12/2022 Report: Key performance indicators (KPIs) to monitor the European clinical trials environment (1-30 November 2022, edition 8)
21/12/2022 Human medicines European public assessment report (EPAR): Exforge HCT, valsartan, hydrochlorothiazide, Amlodipine besilate, Hypertension, 15/10/2009, 23, Authorised
21/12/2022 Human medicines European public assessment report (EPAR): Abecma, idecabtagene vicleucel, Multiple Myeloma; Neoplasms; Cancer; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Infectious Mononucleosis; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases, 18/08/2021, Orphan, Additional monitoring, Conditional approval, 5, Authorised
21/12/2022 Minutes: Minutes of the CAT meeting 3-4 November 2022
21/12/2022 News and press releases: End-of-year message from EMA’s Executive Director
21/12/2022 Annex to CHMP highlights: Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 12-15 December 2022
21/12/2022 Newsletter: Clinical Trials Highlights - December 2022
21/12/2022 Regulatory and procedural guideline: European Medicines Agency post-authorisation procedural advice for users of the centralised procedure
21/12/2022 Regulatory and procedural guideline: European Medicines Agency post-authorisation procedural advice for users of the centralised procedure: document with track changes
21/12/2022 Regulatory and procedural guideline: European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure
21/12/2022 Regulatory and procedural guideline: European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure: document with tracked changes
20/12/2022 Newsletter: Medicinal products for human use: monthly figures - November 2022
20/12/2022 Human medicines European public assessment report (EPAR): Dafiro HCT, valsartan, hydrochlorothiazide, Amlodipine besilate, Hypertension, 03/11/2009, 25, Authorised
20/12/2022 Human medicines European public assessment report (EPAR): Copalia HCT, amlodipine, valsartan, hydrochlorothiazide, Hypertension, 03/11/2009, 23, Authorised
20/12/2022 Clinical Trials Information System (CTIS) bitesize talk: Annual safety report (ASR) , Online, 16:30 - 18:00 Amsterdam time (CET) (Updated), from 15/12/2022 to 15/12/2022
20/12/2022 Website outages and upgrades
20/12/2022 Periodic safety update single assessment: Oxycodone : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002254/202204
20/12/2022 Periodic safety update single assessment: Oxycodone : List of nationally authorised medicinal products - PSUSA/00002254/202204
20/12/2022 Orphan designation: regorafenib for the: Treatment of glioma, 28/06/2019, Withdrawn
20/12/2022 Orphan designation: Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express human alpha-L-iduronidase for the: Treatment of mucopolysaccharidosis type I, 15/10/2021, Withdrawn
20/12/2022 Human medicines European public assessment report (EPAR): Retsevmo, Selpercatinib, Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms, 11/02/2021, Additional monitoring, Conditional approval, 5, Authorised
20/12/2022 Human medicines European public assessment report (EPAR): Olanzapine Glenmark Europe, olanzapine, Schizophrenia; Bipolar Disorder, 03/12/2009, Generic, 14, Authorised
20/12/2022 Human medicines European public assessment report (EPAR): Olanzapine Glenmark, olanzapine, Schizophrenia; Bipolar Disorder, 03/12/2009, Generic, 15, Authorised
20/12/2022 Human medicines European public assessment report (EPAR): Fasturtec, rasburicase, Hyperuricemia, 23/02/2001, 29, Authorised
20/12/2022 First European Medicines Agency - Vaccines Europe meeting , European Medicines Agency, Amsterdam, The Netherlands, from 28/11/2022 to 28/11/2022
20/12/2022 News and press releases: EMA business hours over holiday period
20/12/2022 Direct healthcare professional communication (DHPC): Terlipressin: Serious or fatal respiratory failure and sepsis/septic shock in patients with type 1 hepatorenal syndrome (type 1 HRS), Active substance: terlipressin, DHPC type: Change in dosing recommendation, Last updated: 20/12/2022
19/12/2022 Orphan designation: bevacizumab for the: Treatment of hereditary haemorrhagic telangiectasia, 16/12/2014, Positive
19/12/2022 Other: Release notes - production release version 1.6.13 December 2022 - Veterinary Medicinal Products Regulation: Union Product Database
19/12/2022 Human medicines European public assessment report (EPAR): Bemfola, follitropin alfa, Anovulation, 26/03/2014, Biosimilar, 10, Authorised
19/12/2022 Other: Recommended due dates for centrally authorised products (CAPs) and non-CAPs for submission of the annual statement: January 2023
19/12/2022 Accelerating Clinical Trials in the EU (ACT EU)
19/12/2022 News and press releases: Facilitating Decentralised Clinical Trials in the EU
19/12/2022 CHMP opinions on consultation procedures
19/12/2022 Other: FertiPro N.V. HSA-containing ART media - Procedural steps and scientific information after initial consultation
19/12/2022 Human medicines European public assessment report (EPAR): Jemperli, dostarlimab, Endometrial Neoplasms, 21/04/2021, Additional monitoring, Conditional approval, 6, Authorised
19/12/2022 Human medicines European public assessment report (EPAR): Simbrinza, brinzolamide, brimonidine tartrate, Ocular Hypertension; Glaucoma, Open-Angle, 18/07/2014, 10, Authorised
19/12/2022 Human medicines European public assessment report (EPAR): Posaconazole Accord, posaconazole, Mycoses, 25/07/2019, Generic, 7, Authorised
19/12/2022 Human medicines European public assessment report (EPAR): Axumin, Fluciclovine (18F), Prostatic Neoplasms; Radionuclide Imaging, 21/05/2017, 16, Authorised
19/12/2022 Human medicines European public assessment report (EPAR): Shingrix, Recombinant varicella zoster virus glycoprotein E, Herpes Zoster, 21/03/2018, 9, Authorised
19/12/2022 Patients' and Consumers' Working Party
19/12/2022 Risk management requirements for elemental impurities in veterinary medicinal products, including immunological veterinary medicinal products - Scientific guideline
19/12/2022 Scientific guideline: Concept paper on a guideline on risk management requirements for elemental impurities in veterinary medicinal products, including immunological veterinary medicinal products
16/12/2022 Other: Letter of Support of model-based clinical trial simulation platform (CTSP) for Duchenne Muscular Dystrophy
16/12/2022 News and press releases: EMA Management Board: highlights of December 2022 meeting
16/12/2022 Summary of product characteristics for antiparasitic veterinary medicinal products - Scientific guideline
16/12/2022 Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Waldenstrom Macroglobulinemia, 22/11/2021, Additional monitoring, 4, Authorised
16/12/2022 Human medicines European public assessment report (EPAR): Humira, adalimumab, Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid, 08/09/2003, 89, Authorised
16/12/2022 Referral: Synchron , Article 31 referrals, European Commission final decision, 19/05/2022, 28/11/2022, 16/12/2022
16/12/2022 Work programme: Work plan for the CVMP Novel Therapies & Technologies Working Party (NTWP) 2023
16/12/2022 Human medicines European public assessment report (EPAR): Sivextro, tedizolid phosphate, Soft Tissue Infections; Skin Diseases, Bacterial, 23/03/2015, 20, Authorised
16/12/2022 Opinions and letters of support on the qualification of novel methodologies for medicine development
16/12/2022 Environmental risk assessment of ectoparasiticidal veterinary medicinal products used in cats and dogs
16/12/2022 Work programme: Work plan for the Committee for Veterinary Medicinal Products (CVMP) Environmental Risk Assessment Working Party (ERAWP) 2023
16/12/2022 Work programme: Work plan for the Committee for Veterinary Medicinal Products (CVMP) Efficacy Working Party (EWP-V) 2023
16/12/2022 Scientific guideline: Reflection paper on the environmental risk assessment of ectoparasiticidal veterinary medicinal products used in cats and dogs
16/12/2022 News and press releases: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022
16/12/2022 Summary of opinion: Dimethyl fumarate Accord, dimethyl fumarate, 15/12/2022, Positive
16/12/2022 Summary of opinion: Imjudo, tremelimumab, 15/12/2022, Positive
16/12/2022 Withdrawn application: Imbarkyd, bardoxolone methyl, Date of withdrawal: 09/11/2022, Initial authorisation
16/12/2022 Summary of opinion: Omblastys, iodine (131I) omburtamab, 15/12/2022, Negative
16/12/2022 Summary of opinion: Edistride, dapagliflozin, 15/12/2022, Positive
16/12/2022 Referral: Rambis and associated names , ramipril, bisoprolol fumarate, Ralbior, Article 29(4) referrals, Opinion provided by Committee for Medicinal Products for Human Use, 15/12/2022
16/12/2022 Summary of opinion: Forxiga, dapagliflozin, 15/12/2022, Positive
16/12/2022 Summary of opinion: Tremelimumab AstraZeneca, tremelimumab, 15/12/2022, Positive
16/12/2022 Referral: Pholcodine-containing medicinal products , pholcodine, Article 107i procedures, CMDh position, 14/12/2022, 16/12/2022
16/12/2022 Summary of opinion: Dupixent, dupilumab, 15/12/2022, Positive
16/12/2022 News and press releases: First gene therapy to treat haemophilia B
16/12/2022 Summary of opinion: Hemgenix, etranacogene dezaparvovec, 15/12/2022, Positive
16/12/2022 Summary of opinion: Pombiliti, cipaglucosidase alfa, 15/12/2022, Positive
16/12/2022 Summary of opinion: Fintepla, fenfluramine, 15/12/2022, Positive
16/12/2022 Summary of opinion: Imfinzi, durvalumab, 15/12/2022, Positive
16/12/2022 Summary of opinion: Triumeq, abacavir sulfate / dolutegravir sodium / lamivudine, 15/12/2022, Positive
16/12/2022 Summary of opinion: Imfinzi, durvalumab, 15/12/2022, Positive
16/12/2022 Summary of opinion: Hemlibra, emicizumab, 15/12/2022, Positive
16/12/2022 Summary of opinion: Adcirca (previously Tadalafil Lilly), tadalafil, 16/12/2022, Positive
16/12/2022 Referral: Gelisia and associated names , timolol maleate, Genoptol,Gelisia,Timolol sifi 1 mg/g gel oftalmico, Article 29(4) referrals, Opinion provided by Committee for Medicinal Products for Human Use, 15/12/2022
16/12/2022 Summary of opinion: Kerendia, finerenone, 15/12/2022, Positive
16/12/2022 Orphan designation: Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor (axicabtagene ciloleucel) for the: Treatment of diffuse large B-cell lymphoma, 16/12/2014, Positive
16/12/2022 Human medicines European public assessment report (EPAR): Emadine, emedastine difumarate, Conjunctivitis, Allergic, 27/01/1999, 26, Authorised
16/12/2022 Human medicines European public assessment report (EPAR): Ammonaps, Sodium phenylbutyrate, Ornithine Carbamoyltransferase Deficiency Disease; Citrullinemia; Carbamoyl-Phosphate Synthase I Deficiency Disease, 07/12/1999, 21, Authorised
16/12/2022 Work programme: Work plan for the Committee for Veterinary Medicinal Products (CVMP) Scientific Advice Working Party (SAWP-V) for 2023
16/12/2022 Work programme: Work plan for the Committee for Veterinary Medicinal Products (CVMP) Antimicrobials Working Party (AWP) 2023
16/12/2022 Human medicines European public assessment report (EPAR): Zoely, Nomegestrol acetate, estradiol, Contraception, 26/07/2011, 22, Authorised
16/12/2022 Human medicines European public assessment report (EPAR): Refixia, Nonacog beta pegol, Hemophilia B, 02/06/2017, Additional monitoring, 3, Authorised
16/12/2022 Work programme: CVMP work plan 2023
16/12/2022 Liposomal amphotericin B product-specific bioequivalence guidance
16/12/2022 Scientific guideline: Liposomal amphotericin B powder for dispersion for infusion 50 mg product-specific bioequivalence guidance
16/12/2022 Scientific guideline: Lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg productspecific bioequivalence guidance
16/12/2022 Lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg product-specific bioequivalence guidance
16/12/2022 Agenda: Agenda - Quarterly system demo - Q4 2022
16/12/2022 Work programme: Work plan for the Committee for Medicinal Products for Veterinary Use (CVMP) Pharmacovigilance Working Party (PhVWP-V) 2023
16/12/2022 Q&A: Good clinical practice (GCP)
16/12/2022 Clinical pharmacology and pharmacokinetics: questions and answers
16/12/2022 Other: Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2022
15/12/2022 Human medicines European public assessment report (EPAR): Mysimba, bupropion hydrochloride, naltrexone hydrochloride, Obesity; Overweight, 26/03/2015, Additional monitoring, 23, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Methylthioninium chloride Proveblue, methylthioninium chloride, Methemoglobinemia, 06/05/2011, 25, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Steglujan, ertugliflozin l-pyroglutamic acid, sitagliptin phosphate monohydrate, Diabetes Mellitus, Type 2, 23/03/2018, 9, Authorised
15/12/2022 Other: Science advice on medicines for Human use in the EU medicines regulatory network
15/12/2022 Human medicines European public assessment report (EPAR): Cubicin, daptomycin, Gram-Positive Bacterial Infections; Bacteremia; Soft Tissue Infections; Endocarditis, Bacterial, 19/01/2006, 37, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Cancidas (previously Caspofungin MSD), caspofungin (as acetate), Candidiasis; Aspergillosis, 23/10/2001, 30, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Komboglyze, metformin hydrochloride, saxagliptin hydrochloride, Diabetes Mellitus, Type 2, 24/11/2011, 19, Authorised
15/12/2022 Human variations electronic application forms public training , Online, 10:00 - 11:30 Amsterdam time (CET), from 15/12/2022 to 15/12/2022
15/12/2022 Human medicines European public assessment report (EPAR): Onglyza, Saxagliptin, Diabetes Mellitus, Type 2, 30/09/2009, 21, Authorised
15/12/2022 Ninth industry stakeholder platform on research and development support , Online, from 05/12/2022 to 05/12/2022
15/12/2022 Third Industry Standing Group (ISG) meeting , Online, from 22/11/2022 to 22/11/2022
15/12/2022 Minutes: Meeting summary - Third Industry Standing Group (ISG) meeting
15/12/2022 Human medicines European public assessment report (EPAR): Anagrelide Mylan, Anagrelide hydrochloride, Thrombocythemia, Essential, 15/02/2018, Generic, 6, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Qtern, Saxagliptin, dapagliflozin propanediol monohydrate, Diabetes Mellitus, Type 2; Diabetes Mellitus; Nutritional and Metabolic Diseases; Metabolic Diseases; Glucose Metabolism Disorders, 15/07/2016, 10, Authorised
15/12/2022 EPAR - Scientific conclusion: Alymsys-H-C-PSUSA-00000403-202202 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
15/12/2022 Human medicines European public assessment report (EPAR): Aybintio, bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms, 19/08/2020, Additional monitoring, Biosimilar, 6, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Resolor, Prucalopride succinate, Constipation, 14/10/2009, 29, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Elaprase, idursulfase, Mucopolysaccharidosis II, 08/01/2007, Additional monitoring, Exceptional circumstances, 25, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Advate, octocog alfa, Hemophilia A, 02/03/2004, 31, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Nyxthracis (previously Obiltoxaximab SFL), nyxthracis, Anthrax, 18/11/2020, Orphan, Additional monitoring, Exceptional circumstances, 3, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Padcev, Enfortumab vedotin, Carcinoma, Transitional Cell; Urologic Neoplasms, 13/04/2022, Additional monitoring, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Scemblix, asciminib hydrochloride, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 25/08/2022, Orphan, Additional monitoring, 1, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Neoclarityn, desloratadine, Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal, 15/01/2001, 45, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Abevmy, bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms, 21/04/2021, Additional monitoring, Biosimilar, 5, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Aerius, desloratadine, Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal, 15/01/2001, 49, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Azomyr, desloratadine, Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal, 15/01/2001, 51, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Ecalta, anidulafungin, Candidiasis, 20/09/2007, 24, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Xaluprine (previously Mercaptopurine Nova Laboratories), 6-mercaptopurine monohydrate, Leukemia, Lymphoid, 09/03/2012, 14, Authorised
15/12/2022 Orphan designation: pentosan polysulfate sodium for the: Treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), 21/08/2020, Positive
15/12/2022 Orphan designation: pentosan polysulfate sodium for the: Treatment of mucopolysaccharidosis type I, 19/11/2014, Positive
15/12/2022 Extended EudraVigilance medicinal product dictionary (XEVMPD) training
15/12/2022 Orphan designation: edaravone for the: Treatment of amyotrophic lateral sclerosis, 16/12/2014, Positive
15/12/2022 Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Carcinoma, Non-Small-Cell Lung, 21/09/2018, Additional monitoring, 14, Authorised
15/12/2022 Human medicines European public assessment report (EPAR): Imlygic, talimogene laherparepvec, Melanoma, 16/12/2015, 13, Authorised
15/12/2022 Opinion on medicine for use outside EU: Aluvia, lopinavir, ritonavir, HIV Infections, 21/09/2006, Positive opinion
15/12/2022 Herbal medicinal product: Rosmarini folium, Rosmarini folium, F: Assessment finalised
15/12/2022 Agenda: Agenda for the 118th meeting of the Management Board: 14-15 December 2022
15/12/2022 Other: eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) Data-Entry Tool (EVWEB) user manual
15/12/2022 Human medicines European public assessment report (EPAR): IntronA, interferon alfa-2b, Carcinoid Tumor; Leukemia, Hairy Cell; Lymphoma, Follicular; Hepatitis B, Chronic; Hepatitis C, Chronic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanoma; Multiple Myeloma, 09/03/2000, 34, Withdrawn
15/12/2022 Human medicines European public assessment report (EPAR): Nityr, nitisinone, Tyrosinemias, 26/07/2018, Generic, 3, Authorised
15/12/2022 Herbal – European Union list entry: Draft European Union list entry on Foeniculum vulgare Miller subsp. vulgare var. dulce (Mill.) Batt. & Trab., fructus - Revision 1
15/12/2022 Herbal – European Union list entry: Draft European Union list entry on Foeniculum vulgare Miller subsp. vulgare var. vulgare, fructus - Revision 1
15/12/2022 Herbal medicinal product: Foeniculi amari fructus, Foeniculi amari fructus, F: Assessment finalised
15/12/2022 Herbal medicinal product: Foeniculi dulcis fructus, Foeniculi dulcis fructus, F: Assessment finalised
14/12/2022 Summary of opinion: Enhertu, trastuzumab deruxtecan, 15/12/2022, Positive
14/12/2022 Referral: Nomegestrol and chlormadinone , nomegestrol, chlormadinone, Article 31 referrals, European Commission final decision, 01/09/2022, 28/11/2022, 14/12/2022
14/12/2022 Human medicines European public assessment report (EPAR): Retacrit, epoetin zeta, Anemia; Blood Transfusion, Autologous; Kidney Failure, Chronic; Cancer, 18/12/2007, Biosimilar, 30, Authorised
14/12/2022 Human medicines European public assessment report (EPAR): Gazyvaro, Obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell, 22/07/2014, Orphan, Additional monitoring, 14, Authorised
14/12/2022 Orphan designation: Concizumab for the: Treatment of haemophilia B, 12/10/2017, Withdrawn
14/12/2022 Orphan designation: Humanised monoclonal IgG4 antibody against tissue-factor-pathway inhibitor (concizumab) for the: Treatment of haemophilia A, 10/10/2012, Withdrawn
14/12/2022 Newsletter: Big Data highlights - Issue 4
14/12/2022 Orphan designation: Alisporivir for the: Treatment of collagen VI-related myopathies, 16/03/2022, Positive
14/12/2022 Agenda: Agenda - Human Variations eAF Form training session
14/12/2022 Template or form: EudraVigilance user declaration for qualified person for pharmacovigilance/responsible person for EudraVigilance
14/12/2022 Human medicines European public assessment report (EPAR): Sunosi, solriamfetol hydrochloride, Narcolepsy; Sleep Apnea, Obstructive, 16/01/2020, Additional monitoring, 7, Authorised
14/12/2022 Agenda: Agenda - Joint EMA-FDA workshop: Efficacy of monoclonal antibodies in the context of rapidly evolving SARS-CoV-2 variants
14/12/2022 Orphan designation: besilesomab for the: Treatment in haematopoietic stem cell transplantation, 17/10/2019, Positive
14/12/2022 Human medicines European public assessment report (EPAR): Adtralza, Tralokinumab, Dermatitis, Atopic, 17/06/2021, Additional monitoring, 2, Authorised
14/12/2022 Human medicines European public assessment report (EPAR): Vydura, Rimegepant, Migraine Disorders, 25/04/2022, Additional monitoring, 3, Authorised
14/12/2022 Human medicines European public assessment report (EPAR): Mylotarg, gemtuzumab ozogamicin, Leukemia, Myeloid, Acute, 19/04/2018, Orphan, Additional monitoring, 11, Authorised
14/12/2022 Human medicines European public assessment report (EPAR): Xydalba, dalbavancin hydrochloride, Soft Tissue Infections; Skin Diseases, Bacterial, 19/02/2015, 15, Authorised
14/12/2022 Human medicines European public assessment report (EPAR): Livmarli, Maralixibat chloride, Alagille Syndrome, 09/12/2022, Orphan, Additional monitoring, Exceptional circumstances, Authorised
14/12/2022 Orphan designation: (4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride (maralixibat chloride) for the: Treatment of Alagille syndrome, 18/12/2013, Positive
14/12/2022 Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Neuroblastoma, 08/05/2017, Orphan, Additional monitoring, Exceptional circumstances, 12, Authorised
14/12/2022 Human medicines European public assessment report (EPAR): Imatinib Accord, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Dermatofibrosarcoma; Myelodysplastic-Myeloproliferative Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hypereosinophilic Syndrome, 30/06/2013, Generic, 20, Authorised
14/12/2022 HMA/EMA multi-stakeholder workshop on shortages , European Medicines Agency, Amsterdam, The Netherlands, from 01/03/2023 to 02/03/2023
14/12/2022 Human medicines European public assessment report (EPAR): Repaglinide Krka, repaglinide, Diabetes Mellitus, Type 2, 03/11/2009, Generic, 8, Authorised
14/12/2022 Human medicines European public assessment report (EPAR): Enyglid, repaglinide, Diabetes Mellitus, Type 2, 13/10/2009, Generic, 9, Authorised
14/12/2022 Referral: Veterinary medicinal products containing toltrazuril to be administered orally to chickens , toltrazuril, Article 35, European Commission final decision, 14/07/2022, 09/11/2022
14/12/2022 Human medicines European public assessment report (EPAR): Orladeyo, berotralstat dihydrochloride, Angioedemas, Hereditary, 30/04/2021, 3, Authorised
13/12/2022 Opinion/decision on a Paediatric investigation plan (PIP): Rimiducid, PM: decision on the application for modification of an agreed PIP, P/0418/2019
13/12/2022 Other: European Medicines Agency’s privacy statement for the operation of the Security Access Control System
13/12/2022 Other: Record of data processing activity relating to Security Access Control System (public)
13/12/2022 Human medicines European public assessment report (EPAR): Symtuza, darunavir, cobicistat, emtricitabine, tenofovir alafenamide, HIV Infections, 21/09/2017, 16, Authorised
13/12/2022 Human medicines European public assessment report (EPAR): Rezolsta, darunavir, cobicistat, HIV Infections, 19/11/2014, 15, Authorised
13/12/2022 Clinical Trials Information System (CTIS): Walk-in clinic - January 2023 , Online, 16:00 - 17:00 Amsterdam time (CET), from 18/01/2023 to 18/01/2023
13/12/2022 Clinical Trials Information System (CTIS): Walk-in clinic - February 2023 , Online, 15:00 - 16:00 Amsterdam time (CET), from 16/02/2023 to 16/02/2023
13/12/2022 Clinical Trials Information System (CTIS): Walk-in clinic - March 2023 , Online, 16:00 - 17:00 Amsterdam time (CET), from 16/03/2023 to 16/03/2023
13/12/2022 Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Arthritis, Rheumatoid, 16/12/2019, Patient safety, Additional monitoring, 13, Authorised
13/12/2022 Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course on using the EudraVigilance system , Online, from 10/07/2023 to 14/07/2023
13/12/2022 EudraVigilance training and support
13/12/2022 Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course on using the EudraVigilance system , Online, from 19/06/2023 to 23/06/2023
13/12/2022 Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course on using the EudraVigilance system , Online, from 22/05/2023 to 26/05/2023
13/12/2022 Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course on using the EudraVigilance system , Online, from 17/04/2023 to 21/04/2023
13/12/2022 Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course on using the EudraVigilance system , Online, from 13/03/2023 to 17/03/2023
13/12/2022 Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course on using the EudraVigilance system , Online, from 30/01/2023 to 03/02/2023
13/12/2022 Work programme: Central Nervous System Working Party (CNSWP) work plan 2022-2024
13/12/2022 Agenda: Programme - Clinical Trials Information System (CTIS) sponsor end user training programme
13/12/2022 EPAR - Public assessment report: Zokinvy : EPAR - Public assessment report
13/12/2022 Clinical Trials Information System (CTIS) sponsor end user training programme - February 2023 , Online, 09:00 - 13:00 Amsterdam time (CET), from 07/02/2023 to 10/02/2023
13/12/2022 Clinical Trials Information System (CTIS) sponsor end user training programme - May 2023 , Online, 14:00 - 18:00 Amsterdam time (CEST), from 02/05/2023 to 05/05/2023
13/12/2022 Clinical Trials Information System (CTIS) sponsor end user training programme - June 2023 , Online, 14:00 - 18:00 Amsterdam time (CEST), from 27/06/2023 to 30/06/2023
13/12/2022 Withdrawn application: Hervelous, trastuzumab, Date of withdrawal: 14/09/2022, Initial authorisation
13/12/2022 Withdrawn application: Tuznue, trastuzumab, Date of withdrawal: 14/09/2022, Initial authorisation
13/12/2022 Human medicines European public assessment report (EPAR): Prezista, darunavir, HIV Infections, 11/02/2007, 54, Authorised
13/12/2022 Second European Medicines Agency and Affordable Medicines Europe bilateral meeting , Online, 10:00 - 11:00 Amsterdam time (CET), from 16/11/2022 to 16/11/2022
13/12/2022 Other: eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training: frequently asked questions
13/12/2022 Presentation: Presentation - eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) e-learning - Session 1.0: Introduction
13/12/2022 Human medicines European public assessment report (EPAR): Namuscla, Mexiletine hydrochloride, Myotonic Disorders, 18/12/2018, Orphan, 4, Authorised
13/12/2022 Human medicines European public assessment report (EPAR): Cyramza, Ramucirumab, Stomach Neoplasms, 19/12/2014, 15, Authorised
13/12/2022 Human medicines European public assessment report (EPAR): Ruxience, rituximab, Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid; Microscopic Polyangiitis; Pemphigus, 01/04/2020, Additional monitoring, Biosimilar, 10, Authorised
13/12/2022 Opinion/decision on a Paediatric investigation plan (PIP): Dermatophagoides pteronyssinus,Dermatophagoides farinae, RPM: decision refers to a refusal on the application for modification of an agreed PIP, P/0101/2019
13/12/2022 Opinion/decision on a Paediatric investigation plan (PIP): Chemically modified extract of grass pollen from Holcus lanatus, Phleum pratense and Poa pratensis, RPM: decision refers to a refusal on the application for modification of an agreed PIP, P/0084/2019
13/12/2022 Opinion/decision on a Paediatric investigation plan (PIP): birch pollen,alder pollen, RPM: decision refers to a refusal on the application for modification of an agreed PIP, P/0086/2019
13/12/2022 Opinion/decision on a Paediatric investigation plan (PIP): Testosterone, PM: decision on the application for modification of an agreed PIP, P/0508/2020
13/12/2022 Other: Mandate, objectives and rules of procedure for the CHMP Biologics Working Party (BWP)
13/12/2022 Regulatory and procedural guideline: IRIS guide for parallel distribution applicants
13/12/2022 Human medicines European public assessment report (EPAR): Eviplera, emtricitabine, rilpivirine hydrochloride, tenofovir disoproxil fumarate, HIV Infections, 27/11/2011, 25, Authorised
13/12/2022 Human medicines European public assessment report (EPAR): Scintimun, besilesomab, Osteomyelitis; Radionuclide Imaging, 11/01/2010, 6, Authorised
13/12/2022 Human medicines European public assessment report (EPAR): Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.), formoterol fumarate dihydrate, glycopyrronium, Beclometasone dipropionate, Pulmonary Disease, Chronic Obstructive, 23/04/2018, 4, Authorised
13/12/2022 eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course - February 2023 , Online, 09:00 - 13:00 Amsterdam time (CET), from 13/02/2023 to 15/02/2023
13/12/2022 eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course - May 2023 , Online, 14:00 - 18:00 Amsterdam time (CET), from 10/05/2023 to 12/05/2023
13/12/2022 eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course - July 2023 , Online, 09:00 - 13:00 Amsterdam time (CET), from 03/07/2023 to 05/07/2023
13/12/2022 Human medicines European public assessment report (EPAR): Roclanda, Latanoprost, Netarsudil mesilate, Glaucoma, Open-Angle; Ocular Hypertension, 07/01/2021, Additional monitoring, 4, Authorised
13/12/2022 Human medicines European public assessment report (EPAR): Onivyde pegylated liposomal (previously known as Onivyde), irinotecan anhydrous free-base, Pancreatic Neoplasms, 14/10/2016, Orphan, 11, Authorised
13/12/2022 Work programme: Haematology Working Party (HWP) work plan 2022-2024
13/12/2022 Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Angioedemas, Hereditary, 22/11/2018, Orphan, Accelerated assessment, Additional monitoring, 10, Authorised